Clinical Trial: Evaluation of ICP-B381 in Patients With Advanced Solid Tumors

U.S., Oct. 29 -- ClinicalTrials.gov registry received information related to the study (NCT07901413) titled 'Evaluation of ICP-B381 in Patients With Advanced Solid Tumors' on Oct. 22.

Brief Summary: To evaluate the safety, tolerability, efficacy and pharmacokinetic characteristics of ICP-B381 in the trial participants of advanced solid tumors

Study Start Date: Nov., 2026

Study Type: INTERVENTIONAL

Condition: Advanced Solid Tumor

Intervention: DRUG: ICP-B381

ICP-B381 will be administered by intravenous infusion every 3 weeks (Q3W) until disease progression (PD) or the occurrence of unacceptable toxicity or withdrawal from the study for other reasons (whichever occurs first).

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Beijing I...